Mineralys Therapeutics, Inc. (MLYS)
↓ Download CSVKey ratios (FY2025)
-23.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Income | -$170.60M | -$192.40M | -$84.66M | -$31.48M | — |
| Net Income | -$154.65M | -$177.81M | -$71.90M | -$29.80M | — |
| EPS (Diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 | — |
| Total Assets | $661.81M | $205.90M | $251.64M | $114.44M | — |
| Shareholders' Equity | $646.69M | $191.26M | $241.15M | -$52.27M | -$22.93M |
| Cash & Equivalents | $172.92M | $114.09M | $49.30M | $87.70M | — |
| Operating Cash Flow | -$142.42M | -$166.31M | -$81.17M | -$29.22M | — |
| Capital Expenditures | $15.0K | $96.0K | $0 | — | — |
| Shares Outstanding | 81.54M | 49.82M | 41.13M | 6.42M | — |